Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy by unknown
Escobar et al. BMC Pediatrics 2013, 13:97
http://www.biomedcentral.com/1471-2431/13/97RESEARCH ARTICLE Open AccessPersistent recurring wheezing in the fifth year of
life after laboratory-confirmed, medically
attended respiratory syncytial virus infection in
infancy
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Background: Respiratory syncytial virus (RSV) infection in infancy is associated with subsequent recurrent wheezing.
Methods: A retrospective cohort study examined children born at ≥32 weeks gestation between 1996–2004.
All children were enrolled in an integrated health care delivery system in Northern California and were followed
through the fifth year of life. The primary endpoint was recurrent wheezing in the fifth year of life and its
association with laboratory-confirmed, medically-attended RSV infection during the first year, prematurity, and
supplemental oxygen during birth hospitalization. Other outcomes measured were recurrent wheezing quantified
through outpatient visits, inpatient hospital stays, and asthma prescriptions.
Results: The study sample included 72,602 children. The rate of recurrent wheezing in the second year was 5.6%
and fell to 4.7% by the fifth year. Recurrent wheezing rates varied by risk status: the rate was 12.5% among infants
with RSV hospitalization, 8% among infants 32–33 weeks gestation, and 18% in infants with bronchopulmonary
dysplasia. In multivariate analyses, increasing severity of respiratory syncytial virus infection was significantly
associated with recurrent wheezing in year 5; compared with children without RSV infection in infancy, children
who only had an outpatient RSV encounter had an adjusted odds ratio of 1.38 (95% CI,1.03–1.85), while children
with a prolonged RSV hospitalization had an adjusted odds ratio of 2.59 (95% CI, 1.49–4.50).
Conclusions: Laboratory-confirmed, medically attended RSV infection, prematurity, and neonatal exposure to
supplemental oxygen have independent associations with development of recurrent wheezing in the fifth year of life.
Keywords: Respiratory syncytial virus, Recurrent wheezing, PrematurityBackground
Respiratory syncytial virus (RSV) infection is common
during childhood; attack rates approach 100% by age 3
years [1]. Most infants have mild upper respiratory infec-
tions, but a significant proportion develop more severe
lower respiratory tract disease [1]. The most important
of these infections is bronchiolitis, and RSV is responsible
for 50 to 80% of bronchiolitis hospitalizations and is the
leading cause of hospitalization in children younger than
1 year in the United States [2-4].* Correspondence: gabriel.escobar@kp.org; eileen.m.walsh@kp.org
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reproduction in any medium, provided the orA number of studies have reported an association be-
tween RSV infection and subsequent recurrent wheezing
and early childhood asthma [5-12]. In particular, two re-
cent reports have explored this relationship using large
cohorts. Carroll et al. described the association between
full-term children who had outpatient visits or hospitali-
zations for bronchiolitis in infancy and asthma in the
sixth year of life [13]. They demonstrated the presence
of a severity gradient (increased severity of bronchiolitis
correlated with increased asthma severity). Using a more
rigorous, laboratory-confirmed definition for RSV infec-
tion, our team previously reported a similar relationship
between RSV infection and recurrent wheezing in thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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infants [14].
In this report, we describe the outcomes of a cohort of
children born at ≥32 weeks gestational age (GA) who
were followed through the fifth year of life. Because the
association between RSV infection and asthma has been
reported to decrease as the age of follow-up increases
[5,6,15,16], we wanted to address this issue with an ex-
panded cohort with two additional years of follow-up.
Our goal was to quantify the relationship between
laboratory-confirmed, medically attended RSV infection in
the first year of life with the presence of recurrent wheezing
(RW) during a time period when the prevalence of these
conditions is expected to decrease [17]. We also explored
the degree to which the relationships we found were
dependent on the RW definition.
Methods
Study design
We collected data from Kaiser Permanente Northern
California (KPNC), an integrated health care delivery sys-
tem. This study was approved by the KPNC Institutional
Review Board, which has jurisdiction over all the hospitals
and clinics involved in this study. The inception cohort,
described in detail in our previous report [14], included
infants meeting the following criteria: birth at the KPNC
Oakland, Hayward, Sacramento, San Francisco, Santa Clara,
or Walnut Creek hospitals; date of birth from 1/1/96
through 12/31/04 (this study added infants born between
1/1/03 through 12/31/04; our previous cohort included
births through 12/31/02); ≥32 weeks GA at birth; infant
survived the birth hospitalization; and use of or mem-
bership in Kaiser Foundation Health Plan, Inc. during
the first year of life.
Study outcomes
Our primary study outcome was the occurrence of RW
in the fifth year of life (fourth birthday through the day
before the fifth birthday; henceforth, RW5). We defined
RW as in our previous report using a combination of
encounter events, patient diagnoses, and prescription
patterns [14]. Using this definition, we determined whether
children in our cohort met this definition in years 2, 3, 4,
and 5 as well as examining the prevalence of any RW
across years 2 through 5. We also tested a lenient definition
termed “tentative asthma diagnosis” (TAD) in which we
accepted any instance of International Classification of
Diseases (ICD9) [18] diagnosis code for asthma (493.xx)
in a given year at face value (i.e., we did not have strict
criteria for number of encounters, nor did we use pre-
scription data). Children categorized with TAD during
years 2 through 5 were sorted into 4 hierarchical, mutually
exclusive categories based on the year of life in which they
were diagnosed.Predictors
The primary study predictor was the occurrence of
laboratory-confirmed, medically attended RSV infection
in the first year of life (henceforth, “RSV infection”). We
also examined whether infants were infected with
adenovirus, parainfluenza virus, influenza A or B virus, or
Bordetella pertussis. We considered outpatient visits, emer-
gency department (ED) visits, and inpatient hospitalization
with diagnosis codes for each type of pathogen to be medic-
ally attended events. A medically attended event was con-
sidered to be laboratory-confirmed if there was a positive
test for the pathogen within ±14 days of the encounter.
Pathogens were identified using direct fluorescent antibody
testing or culture. We categorized medically attended
encounters for RSV and other pathogens as outpatient
(including scheduled clinic visits, unscheduled urgent
care visits, and ED visits), uncomplicated hospitalizations
(hospitalizations with a total length of stay [LOS] <96 hours
without assisted ventilation), or prolonged hospitalizations
(hospitalizations lasting ≥96 hours or in which assisted
ventilation occurred). Race was included as a predictor
and assessed in this study because of the well-known
differences in RSV infection severity by race. The other
predictors — infant sex, maternal age, birth weight,
GA, small for GA status, oxygen exposure during the
neonatal period, family history of asthma as found in
physicians’ Significant Problem List or because of parental
visits for asthma, bronchopulmonary dysplasia, presence
of congenital anomalies, number of siblings present in the
home, and hospitalizations for unspecified respiratory
illnesses — were defined as previously reported [14].
Attrition
To be included in our main analyses, each child in the
cohort had to be a member for at least 9 months in each
of the first five years of life. To make this determination,
we linked the study children’s utilization and membership
data and created a monthly membership variable which was
set equal to 1 (patient was a member during that month
and/or had outpatient or inpatient use during that month)
or 0 (patient was not a member during that month and did
not have outpatient or inpatient use during that month) to
determine eligibility for inclusion in the study cohort.
Data collection
The KPNC information systems employ a common medical
record number for all inpatient, outpatient, and administra-
tive encounters in all facilities, permitting extraction and
linkage of patient data using methods that have been previ-
ously described [19-22]. Care received outside the program
was also tracked. We identified infants using the KPNC
hospitalization database and the Neonatal Minimum Data
Set [23], a database that captures supplemental oxygen use
and assisted ventilation among infants receiving neonatal
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demographic, membership, laboratory, pharmacy, out-
patient encounter, and hospitalization databases to obtain
the previously described variables.
Statistical analyses
Statistical analyses were conducted using SAS (SAS
Institute, Cary, NC). Unadjusted odds ratios (ORs) for
all predictors were calculated using logistic regression
[24] with RW5 as the outcome and each of the predictors
as the only explanatory variable. Values of categorical
variables were compared using a chi-square or Fisher
exact test. Normally distributed continuous variables
were compared using a Student t test. Comparisons of
non-normally distributed continuous variables employed
the Wilcoxon rank sum test.
We conducted multivariate analyses in three ways. We
employed both logistic regression models in which children
were included based on the abovementioned membership
criteria as well as Cox proportional hazards modeling [24]
(to account for censoring of infants). Because the results
of Cox models were similar, we report those results in
Additional file 1 Table S1; logistic regression models
are reported in this paper. We also performed logistic
regression using RW2, RW3, RW4, and RW5 cohorts
so that we could assess the change in association as the
length of follow-up increased.
The relative contribution of each predictor was calculated
using the differences between the log likelihood of the
full model and the log likelihood of a model without
each of the predictors and was defined as the ratio of its
log likelihood difference to the sum of the likelihood
differences from all predictors × 100 [25].
Results
Study participants
Scanning KPNC databases identified 165,366 infants who
survived to discharge from the birth hospitalization
during 1996–2004. Infants were excluded from the study
due to missing data (n=358), prematurity (<32 weeks GA
[most received RSV immunoprophylaxis]; n=2,371) and
not meeting membership criteria (n=19,913). The final
study cohort consisted of 142,724 infants ≥32 weeks
GA. Of these, 72,602 met membership criteria during
the first 5 years of life and constitute the analysis cohort.
Among these infants, 43,786, or 60.3%, were also in our
original cohort. Additional details, including a cohort
assembly flow chart, are available in Additional file 1
Figures S1 and S2.
Subject demographics are reported in Table 1. The
study population is ethnically diverse, and the majority
of mothers (73%) were 18–34 years of age. Using maternal
records, we determined that 3.6% of infants had a maternal
history of asthma.RSV infection and the prevalence of recurrent wheezing
Using logistic regression, documented RSV infection in
the first year of life was associated with an increased risk
of RW5, and a severity gradient was evident (Table 2). For
example, RSV infection that only involved an outpatient
encounter had an adjusted odds ratio (AOR) of 1.38
(95% CI, 1.03–1.85), whereas if it involved prolonged
hospitalization the AOR was 2.59 (95% CI, 1.49–4.50).
Exposure to oxygen in the neonatal period also showed
a similar gradient. In contrast, infections with other
pathogens were not associated with increased rates of
RW5, although prolonged hospitalizations with unspecified
organisms did show a strong association (AOR, 3.46,
95% CI, 1.94–6.16). Gestational age <37 weeks was also
associated with increased risk of RW5 (Table 2). The
relative contribution of RSV infection to the overall
predictive ability of our model was 6.6%, whereas the
relative contribution of oxygen exposure was 4.9%. In
contrast, the relative contribution of non-modifiable
risk factors was 22.8% for sex, 4.8% for GA, 21.2% for
race, and 28.7% for family history of asthma.
The prevalence of RW by individual years and across
years 2 through 5 is reported in Table 3. Across all chil-
dren, the prevalence of RW decreased over time from
5.6% in year 2 to 4.7% in year 5. However, depending on
the presence of risk factors, the rate of RW in year 2 and
the rate of decline during early childhood may be sub-
stantially different. For example, 25.0% of children with
laboratory-confirmed RSV hospitalization in their first
year had RW in the second year of life. These infants
were approximately three times as likely to have RW5 than
children who did not (12.5% vs. 4.6%), and approximately
three times as likely to ever have had RW in years 2–5
(40.0% vs 12.3%). Figure 1 shows that a severity gradient
(increased severity of RSV infection in infancy is associated
with an increased prevalence of RW) is evident across
the second through fifth years of life. The association
between RSV infection, RW, and prematurity is reported
in Additional file 1 Figure S3, which provides additional
displays of this gradient among children born at <37
and ≥37 weeks GA. In addition, the AOR for all types of
RSV infection tended to fall as the dependent variable was
changed from RW2 to RW5. For example, the AORs for
an outpatient RSV encounter for RW2 through RW5 were
3.18, 2.21, 2.11, and 1.36. Additional results are shown in
Additional file 1 Table S3.
Use of a more lenient tentative asthma diagnosis to
capture RW events did not lead to any directional change
in our findings, but rather a general increase in the preva-
lence of reported outcomes. The proportion of children
with RW5 using our strict definition was 4.6%, but
increased to 10.3% when using the more lenient definition;
however, the overall trends in the data remained consistent.
Tabular data using this alternative definition is shown in
Table 1 Description of infants born during 1996–2004 by gestational age categories
Gestational age, wk
32–33 34–36 37 38–40 ≥ 41 All gestational ages
N 936 4,665 4582 51,049 11,370 72,602
Male sex, % 51.07 54.81 53.40 50.44 50.71 50.96
Race, %*
White 46.79 43.09 39.90 42.87 47.65 43.50
African-American 11.32 10.40 9.41 8.57 9.30 8.89
Asian 16.35 19.85 23.42 20.74 15.27 19.94
Hispanic 16.99 18.93 20.32 21.25 20.81 20.92
Other/unknown 8.55 7.74 6.96 6.56 6.97 6.75
Maternal age, y, %
<18 2.24 1.29 1.18 1.19 1.49 1.25
18–34 67.20 68.75 70.76 73.58 74.64 73.17
>35 30.56 29.97 28.07 25.23 23.87 25.57
Family history of asthma, %†
None 93.91 94.23 94.43 94.82 95.15 94.80
Father only 2.03 1.63 1.66 1.49 1.37 1.50
Mother only 4.06 4.14 3.84 3.60 3.42 3.63
Both parents 0.00 0.00 0.07 0.09 0.06 0.08
31 sibling <5 y of age in home, % 42.95 42.17 39.57 39.51 32.22 38.58
Congenital anomaly present, %‡ 13.14 10.33 7.77 6.52 6.24 6.88
Small for gestational age, %§ 4.59 3.41 2.23 1.25 0.67 1.40
Oxygen exposure|| and BPD, %¶
No oxygen, no BPD 55.77 86.13 96.49 97.77 96.31 96.17
<200 hours oxygen, no BPD 37.50 12.24 3.12 1.95 3.26 3.35
3200 hours oxygen, no BPD 5.24 1.29 0.37 0.25 0.40 0.41
BPD 1.50 0.34 0.02 0.03 0.04 0.07
Unspecified respiratory hospitalization %# 15.92 15.05 12.40 8.09 7.19 8.77
Laboratory-confirmed, medically attended
RSV infection, %**
3.95 2.98 2.14 1.64 1.36 1.74
Admitted to hospital, %‡‡ 2.46 1.31 0.87 0.63 0.49 0.69
Treated as outpatient, %§§ 1.50 1.67 1.27 1.00 0.87 1.05
Laboratory-confirmed, medically attended
infection with other pathogen, %††
0.64 0.58 0.31 0.28 0.25 0.30
Admitted to hospital, %‡‡ 0.53 0.28 0.13 0.13 0.11 0.14
Treated as outpatient, %§§ 0.11 0.3 0.17 0.16 0.14 0.16
Abbreviations: BPD Bronchopulmonary dysplasia, CI Confidence interval, RSV Respiratory syncytial virus, wk week, y year.
*Classification of race/ethnicity in this study was based on the race of infants' mothers, as self-reported to the birth certificate clerk interviewing them at the
Kaiser Permanente hospitals described in this study. Race was assessed in this study because of the well-known differences in RSV infection severity by race.
†Ascertained by electronic scanning of parental records, which included encounters and diagnoses identified in the Significant Problem List by the
parent’s physician.
‡See text for list of included International Classification of Diseases codes.
§Based on the algorithm of Brenner WE, et al. Am J Obstet Gynecol. 1976;126:555–564.
||Oxygen exposure, in hours, during the birth hospitalization. See text for details.
¶All infants with BPD had ≥200 hours of oxygen exposure during the neonatal period.
#Hospitalization for pneumonia or other respiratory illness without laboratory confirmation for RSV or the other pathogens listed in footnote ††.
**Medically attended visit where positive RSV direct fluorescent antibody test or viral culture occurred within ± 14 days of visit.
††Medically attended encounter where a positive test result (direct fluorescent antibody test, viral culture, or bacterial culture) for adenovirus, influenza virus,
parainfluenza virus 1 or 2, or Bordetella pertussis occurred within ± 14 days of encounter.
‡‡ The encounter included a hospital admission.
§§ The encounter included outpatient care only.
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Table 2 Risk factors for recurrent wheezing in the fifth
year of life using logistic regression*
Beta Adjusted
odds ratio
95% CI P Value
Sex




African-American 0.53 1.71 1.52–1.91 <.0001
Asian 0.31 1.36 1.24–1.49 <.0001
Hispanic 0.10 1.11 1.01–1.22 0.0356
Other/unknown 0.22 1.25 1.09–1.44 0.0020
Maternal age, y
<18 −0.07 0.94 0.69–1.28 0.6764
18–34 reference
≥35 0.04 1.04 0.96–1.13 0.3321
Family history of asthma†
Unknown reference
Father only 0.59 1.81 1.44–2.27 <.0001
Mother only 0.76 2.15 1.87–2.47 <.0001
Both parents 0.53 1.70 0.61–4.71 0.3109
Siblings <5 y of age
in house
None reference
≥1 −0.15 0.86 0.80–0.92 <.0001
Congenital anomaly†
Present 0.13 1.14 1.00-1.29 0.0493
Absent reference
Small for gestational age†
No reference
Yes −0.04 0.96 0.72–1.28 0.7822
Gestational age, wk
32–33 0.40 1.49 1.15–1.92 0.0022
34–36 0.26 1.30 1.14–1.48 <.0001
37 0.11 1.12 0.98–1.29 0.1049
38–40 reference
≥41 −0.06 0.95 0.85–1.05 0.2717




<200 hours oxygen, no BPD 0.28 1.32 1.12–1.57 0.0012
≥200 hours oxygen, no BPD 0.69 2.00 1.37–2.90 0.0003




Table 2 Risk factors for recurrent wheezing in the fifth
year of life using logistic regression* (Continued)
Uncomplicated
hospitalization
0.50 1.65 0.98–2.79 0.0594





Outpatient visit only 0.32 1.38 1.03–1.85 0.0307
Uncomplicated
hospitalization
0.68 1.98 1.39–2.81 0.0002





Outpatient visit only 0.26 1.30 0.62–0.69 0.4883
Uncomplicated
hospitalization
0.32 1.38 0.54–3.52 0.4981
Prolonged hospitalization 0.74 2.10 0.76–5.80 0.1526
Abbreviations: BPD Bronchopulmonary dysplasia, CI Confidence interval, RSV
Respiratory syncytial virus, wk week, y year.
*Based on study cohort of 72,602 children, of whom 3380 had recurrent
wheezing in the fifth year of life. See text for description of cohort and
definition of recurrent wheezing. Results have been adjusting for infant and
mother demographic and clinical characteristics.
†Please refer to the appropriate section of the footnotes to Table 2 for
further details.
‡Percent adherence to recommended course per AAP guidelines, see online
appendix for details of how adherence was calculated.
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are available upon request by interested readers.
Recurrent wheezing in preterm and term infants
We quantified the occurrence of any RW episode
(outpatient or inpatient encounter with ICD diagnosis
493.xx) across all study years in term and premature
infants. This approach demonstrated higher rates of
RW encounters among infants with RSV infection com-
pared with infants without RSV infection and also a gradi-
ent by severity of RSV infection. Approximately 30%–60%
of premature infants 32–36 weeks GA with RSV infection
during the first year of life will have a recurrent wheezing
episode by age 5 years and 40% will have >1 episode. The
overall rate of inpatient encounters with a wheezing diag-
nosis among premature infants without RSV infections in
infancy was 56 per 1,000 children by age 5 years, whereas
the rate among those that did have RSV infection was 102
per 1,000 children; the corresponding rates for term infants
were 27 and 111, respectively. With respect to outpatient
encounters, the respective rates were 1,097 and 2,352 per
1,000 children for premature infants and 743 and 2,152 for
term infants.
Table 3 Recurrent wheezing during study period
RW 2nd Year RW 3rd Year RW 4th Year RW 5th Year RW 2nd–5th Years
N n % n % n % n % n %
All children 72,602 4,091 5.6 3,492 4.8 3,466 4.8 3,380 4.7 9,151 12.6
Sex
Female 35,606 1,402 3.9 1,261 3.5 1,318 3.7 1,330 3.7 3,499 9.8
Male 36,996 2,689 7.3 2,231 6.0 2,148 5.8 2,050 5.5 5,652 15.3
Race*
White 31,580 1,650 5.2 1,443 4.6 1,353 4.3 1,265 4.0 3,642 11.5
African-American 6,454 517 8.0 409 6.3 420 6.5 441 6.8 1,093 16.9
Asian 14,476 807 5.6 774 5.3 785 5.4 764 5.3 1,983 13.7
Hispanic 15,189 876 5.8 644 4.2 670 4.4 664 4.4 1841 12.1
Other/unknown 4,903 241 4.9 222 4.5 238 4.9 246 5.0 592 12.1
Maternal age, y
<18 911 55 6.0 38 4.2 37 4.1 44 4.8 118 13.0
18–34 53,125 3,068 5.8 2,530 4.8 2,571 4.8 2,453 4.6 6,779 12.8
≥35 18,566 968 5.2 924 5.0 858 4.6 883 4.8 2,254 12.1
Family history of asthma*
None 68,824 3,698 5.4 3,131 4.5 3,135 4.6 3,053 4.4 8,320 12.1
Father only 1,087 91 8.4 94 8.6 92 8.5 83 7.6 220 20.2
Mother only 2,633 294 11.2 258 9.8 232 8.8 240 9.1 596 22.6
Both parents 58 8 13.8 9 15.5 7 12.1 4 6.9 15 25.9
Sibling aged <5 y in home
None 44,590 2,358 5.3 2,127 4.8 2,246 5.0 2,197 4.9 5,631 12.6
≥1 28,012 1,733 6.2 1,365 4.9 1,220 4.4 1,183 4.2 3,520 12.6
Congenital anomaly*
Absent 67,605 3,739 5.5 3,176 4.7 3,170 4.7 3,079 4.6 8,371 12.4
Present 4,997 352 7.0 316 6.3 296 5.9 301 6.0 780 15.6
Small for gestational age*
No 71,582 4,011 5.6 3,424 4.8 3,405 4.8 3,328 4.6 8,989 12.6
Yes 1020 80 7.8 68 6.7 61 6.0 52 5.1 162 15.9
Gestational age, wk*
32–33 936 99 10.6 81 8.7 78 8.3 75 8.0 188 20.1
34-36 4,665 401 8.6 290 6.2 294 6.3 294 6.3 793 17.0
37 4,582 270 5.9 264 5.8 209 4.6 238 5.2 635 13.9
38–40 51,049 2,763 5.4 2,373 4.6 2,345 4.6 2,290 4.5 6,235 12.2
≥41 11,370 558 4.9 484 4.3 540 4.7 483 4.2 1,300 11.4
Oxygen exposure* and BPD*
No oxygen, no BPD 6,9821 3,819 5.5 3,267 4.7 3,249 4.7 3,162 4.5 8,607 12.3
<200 h Oxygen, no BPD 2,431 221 9.1 177 7.3 165 6.8 173 7.1 445 18.3
≥200 h Oxygen, no BPD 300 43 14.3 34 11.3 45 15.0 36 12.0 80 26.7
BPD 50 8 16.0 14 28.0 7 14.0 9 18.0 19 38.0
Unspecified respiratory hospitalization*
None 72,345 4017 5.6 3,449 4.8 3,420 4.7 3,348 4.6 9,052 12.5
Uncomplicated hospitalization 177 47 26.6 24 13.6 26 14.7 16 9.0 64 36.2
Prolonged hospitalization 80 27 33.8 19 23.8 20 25.0 16 20.0 35 43.8
Escobar et al. BMC Pediatrics 2013, 13:97 Page 6 of 9
http://www.biomedcentral.com/1471-2431/13/97
Table 3 Recurrent wheezing during study period (Continued)
Laboratory-confirmed, medically attended
RSV infection*
None 71,336 3,829 5.4 3,326 4.7 3,312 4.6 3,280 4.6 8,748 12.3
Outpatient 762 127 16.7 79 10.4 74 9.7 50 6.6 201 26.4
Uncomplicated hospitalization 384 105 27.3 67 17.4 57 14.8 35 9.1 154 40.1
Prolonged hospitalization 120 30 25.0 20 16.7 23 19.2 15 12.5 48 40.0
Laboratory-confirmed, medically attended
infection with other pathogen*
None 72,382 4,056 5.6 3,476 4.8 3,449 4.8 3,362 4.6 9,101 12.6
Outpatient 119 20 16.8 7 5.9 7 5.9 8 6.7 30 25.2
Uncomplicated hospitalization 64 7 10.9 3 4.7 5 7.8 5 7.8 10 15.6
Prolonged hospitalization 37 8 21.6 6 16.2 5 13.5 5 13.5 10 27.0
Definite, medically attended RSV encounter
in the first year of life*
No 71,336 3,829 5.4 3,326 4.7 3,312 4.6 3,280 4.6 8,748 12.3
Yes 1,266 262 20.7 166 13.1 154 12.2 100 7.9 403 31.8
Abbreviations: BPD Bronchopulmonary dysplasia, RSV Respiratory syncytial virus, RW Recurrent wheezing, wk weeks, y years.
*Please refer to the appropriate section of the footnotes to Table 1 for further details.
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In this retrospective cohort study of children born at ≥32
weeks GA, we found that three important risk factors
(RSV disease in the first year of life, moderate prematurity,
and exposure to supplemental oxygen in the neonatal
period) had statistically significant associations with the
development of RW5. This is consistent with our previous
report, [14] where these predictors were associated with
RW in the third year of life. Our study is concordant with
and expands upon the study by Carroll et al. [13]. As was
the case with that study, ours is a very large cohort, but
ours had the advantage of including children born at <37Figure 1 Relationship between respiratory syncytial virus infection enc
through 5 of life. Encounter types are hierarchical (prolonged hospitalization
and mutually exclusive. RSV=respiratory syncytial virus.weeks gestation as well as actually documenting RSV
infection, rather than just using the presence of a bron-
chiolitis diagnosis. Our study also found that other
pathogens did not show a strong association. We also
found that, consistent with the known epidemiology of
asthma and RW, prevalence decreases over time, but
among infants with certain risk factors including RSV
infection, the prevalence of RW remained high in the
fifth year. We found that these relationships persisted
when we employed a more lenient definition of RW
(accepting any instance of an asthma diagnosis). Future
studies may be needed to better characterize the burdenounters in year 1 with prevalence of recurrent wheezing in years 2
supersedes hospitalization, which supersedes outpatient encounter only)
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whether other strategies for mitigating the effects of RSV
are possible. It is important to stress that our study is not
in concordance with another very large study conducted
in Finland, where Dunder et al. did not find an association
between RSV epidemics and subsequent use of asthma
medication [26]. The study by Dunder et al. is important
because, like us, electronic scanning of asthma medications
was employed for ascertainment.
In our previous report [14], we pointed out a number
of limitations to our findings, of which the most import-
ant was that not all infants in our cohort were tested for
RSV. Nonetheless, the presence of a severity gradient,
the fact that the RSV effect observed in the third year of
life persists into the fifth year, and the fact that other
pathogens do not show this association, strongly support
the notion that RSV infection in infancy is associated
with asthma in childhood. This notion has been suggested
by others [5-9]. However, it is important to note that
some of our findings could be interpreted differently.
For example, while it is true that our analyses clearly
show a specific effect of documented RSV infection, it
is striking that the relative contribution of this variable
to the overall predictive ability of our model is small
(6.6%), while the contribution of non-modifiable risk
factors such as sex, race, and family history was far greater.
In this context, we must note that our lack of data on
tobacco exposure is a significant limitation.
The presence of an association, however strong, does
not constitute evidence of causality, and it is important
to consider a number of possible causal paths, which are
not mutually exclusive, that could explain our findings.
The relationship of lower respiratory tract RSV disease to
asthma is under investigation, particularly the role of gen-
etic susceptibility for eventual asthma and the interaction
of genetic susceptibility with the environment [27-29]. It
remains unclear whether RSV infection disrupts neural
control of bronchiolar smooth muscle setting the stage
for sensitized airways or whether RSV disease serves as
an additional insult to a host with pre-existing genetic
susceptibility for eventual asthma [27,30-33]. One possi-
bility is that infection with RSV causes lung damage that
ultimately leads to the development of asthma. Such dam-
age could be accentuated by oxygen exposure, prematur-
ity, bronchopulmonary dysplasia, and/or environmental
exposures (e.g., air pollution, secondhand smoke). Another
possibility is that a set of genes exists that is preferentially
expressed following infection with RSV. Such genes, which
could also be affected by environmental factors, could lead
to the occurrence of wheezing and asthma. It is also
possible that a set of genes that are not identical to,
but are related to, the development of asthma also code
for a more exaggerated response to RSV infection, thus
explaining the severity gradient noted by us and others.Lastly, one cannot exclude the possibility that a subset
of the population requires a severe RSV infection in
order to develop asthma.
Given conflicting findings in the literature, with different
studies and study types (e.g., twin studies) coming to differ-
ent conclusions [28,34,35], a definitive explanation of the
relationship of RSV infection to the development of asthma
remains elusive [36]. What is clear is that future studies
need to include more detail with respect to direct capture
of genetic information. It is instructive to outline the com-
ponents of what could be considered an optimal prospect-
ive study to explore the relationship between RSV infection
in infancy and the development of asthma. Ideally, infants
should be enrolled immediately after birth, and the initial
intake process should include non-invasive collection of in-
fant and parental DNA and a detailed history that includes
special attention to family smoking history, history of atopy
in parents and grandparents, and other possible environ-
mental and allergen exposures (e.g., pets in the home).
Subsequent follow-up should include frequent testing for
respiratory pathogens [37], careful attention to the devel-
opment of atopy, and an objective assessment of whether
or not a child develops wheezing. The setting for such a
study should be in an ethnically diverse population with a
relatively high baseline prevalence of asthma.
Conclusions
We have found that predictors for recurrent wheezing
in the third year of life also predict for recurrent
wheezing in the fifth year. Of these, the most import-
ant potentially modifiable predictor was documented
laboratory-confirmed, medically attended RSV infection in
the first year of life. Future research in this area will need
to incorporate genetic data collection, since purely obser-
vational studies do not permit definitive inferences as to
causal pathways responsible for the association between
RSV infection and subsequent wheezing.
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